Type 1 diabetes: Prescription of GLP-1 receptor agonists and SGLT2 inhibitors

被引：0
|
作者：
Simon, Annika
机构：
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2025年 / 20卷 / 01期
关键词：
D O I：
10.1055/a-2451-3561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Two relatively new classes of antidiabetic drugs - GLP-1 receptor agonists (GLP-1-RAs) and SGLT2 inhibitors (SGLT2-Is) - show positive effects on cardiovascular mortality and weight management in people with type 2 diabetes. Since there is also evidence that patients with type 1 diabetes could also benefit, Li et al. conducted a data analysis on current prescribing practices.
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [2] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [3] Prescription Patterns for GLP-1 Receptor Agonists and SGLT2 Inhibitors by Physicians' Years in Practice
    Inoue, Kosuke
    Kazi, Dhruv S.
    Vaduganathan, Muthiah
    Wadhera, Rishi K.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2025,
  • [4] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [5] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [6] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [7] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [8] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [9] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [10] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
12345